Stock Guru Profile HSXI
The HealthSonix: Arthritis Treatment Centers fully addresses the gray market’s questions and needs regarding arthritis and in that venue supplies a real solution for pain relief. The enSonix and AquaSonix line of medical products rely on sound pressure wave technology which represents a medical breakthrough in the fight against the pain of arthritis. HealthSonix is working to patent this crucial techology.
The Patent Cooperation Treaty (PCT) was established to provide an efficient and cost-effective way to enter into the patenting process in many different countries at one time. Most of the countries in the world are signatories to the Paris Convention. The PCT permits the filing of an “international” patent application either immediately or within one year of the filing of a patent application in any of the member nations. This filing now gives HealthSonix the ability to file for additional international patents over the next 18 months while retaining the original US priority filing date.
Medical Products Which Target Arthritis Will Continue to be in Large Demand
Osteoarthritis is the most common form of arthritis. In 2006 there were 46 million or nearly 1 in 5 adults diagnosed with arthritis. 23.2 million additional people live with chronic joint symptoms, but have not been diagnosed by a doctor
Arthritis is currently second only to chronic heart problems in worksite disabilities. It is more prevalent in females than males, due mainly to hormonal differences between the genders. The incidence of Osteoarthritis will continue to rise over the next decade due to the aging population, particularly growth in the number of persons over the age of 55. Another factor driving the incidence of Osteoarthritis in the Western world is the increasing prevalence of obesity, as obesity augments predisposition to Osteoarthritis, particularly in the knee.
The Osteoarthritis patient population is generally estimated at 12% of the adult population, a figure that will increase as demographic shifts occur. This estimate places the number of Osteoarthritis patients in the seven major markets at 70 million in 2002. The global arthritis market was worth around $15.5bn in 2002. Non-steroidal anti-inflammatories contributed 75% of total sales and disease-modifying anti-rheumatic drugs a further 18%.
Sources:
Business Insights Limited
HealthSonix
Arthritis Foundation – http://www.arthritis.org/resources/gettingstarted/default.asp
United Nations (2005)
HealthSonix Inc.
14252 Culver Drive
Suite 107
Irvine CA 92604-0317
Tel: (949)417-8880
Fax: (949)271-3760
www.HealthSonix.com
About HealthSonix Inc.: HealthSonix Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company’s core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects.
Forward Loooking Statement: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .
Disclosure: Pentony Enterprises LLC was compensated $12,500 from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
